DOSE OF REALITY: PATENT HEARINGS OFFER OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE FOR ANTI-COMPETITIVE PRACTICES
Jun 22, 2022
Lawmakers Can Highlight Tactics Designed to Block More Affordable Alternatives… Read More
© 2026 CSRXP- All Rights Reserved
Dose of Reality
DOSE OF REALITY: BIG PHARMA TARGETS MERGERS AND ACQUISITIONS TO KEEP PRICES HIGH, EXTEND MONOPOLIES AND BOOST PROFITS
Jun 13, 2022
FTC Workshop Can Highlight How Brand Name Drug Companies Employ… Read More
DOSE OF REALITY: SENATE COMMERCE HEARING OPPORTUNITY FOR LAWMAKERS TO HOLD BIG PHARMA ACCOUNTABLE
May 3, 2022
Lawmakers Should Focus Attention on Brand Name Drug Companies’ Egregious… Read More
DOSE OF REALITY: NEW STUDY FINDS ONE THIRD OF SENIORS DO NOT FILL PRESCRIPTIONS FOR HIGH-PRICE DRUGS USED TO TREAT SERIOUS CONDITIONS
Apr 6, 2022
Academic Study Underscores How Big Pharma’s Price-Gouging on Treatments for… Read More
DOSE OF REALITY: LAWMAKERS MUST HOLD BIG PHARMA ACCOUNTABLE IN SENATE FINANCE HEARING
Mar 14, 2022
Congress Can Refocus Attention on Market-Based Solutions to Crack Down on… Read More
DOSE OF REALITY: NEW ANALYSIS UNDERSCORES HOW OFTEN BIG PHARMA’S PATENTS ARE UNRELATED TO CLINICAL INNOVATION
Jan 19, 2022
Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for… Read More
DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART I
Dec 28, 2021
Part I: Price-Gouging An Unproven Treatment, Setting Out-of-Control Launch… Read More
DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART II
Dec 28, 2021
Part II: Pushing Debunked Innovation Rhetoric to Oppose Rx Solutions Despite… Read More
DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART III
Dec 28, 2021
Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual… Read More
DOSE OF REALITY: OVERSIGHT REPORT EXPOSES BIG PHARMA’S EGREGIOUS PRICING & ANTI-COMPETITIVE TACTICS — DEBUNKS INNOVATION RHETORIC
Dec 12, 2021
Investigation Finds Big Pharma Hiked Prices More Than 250 Times On Just 12 Top… Read More
DOSE OF REALITY: LAWMAKERS TO PROBE BIG PHARMA PATENT ABUSE AS INNOVATION EXCUSES CRUMBLE
Jul 13, 2021
U.S. Senate Judiciary Subcommittee Hearing Tuesday Will Build on Momentum for… Read More
DOSE OF REALITY: HUMIRA: A CASE STUDY IN BIG PHARMA GREED
May 17, 2021
AbbVie CEO Headed for Capitol Hill to Answer for Indefensible Anti-Competitive… Read More